Alimera Sciences Announces Nine iluvien® data sets to be Presented at 2017 american academy of ophthalmology
"We are delighted that nine ILUVIEN data sets have been accepted for presentation at the Academy this year," said
The presentations are scheduled as follows:
From the podium:
9:18 a.m. - 9:25 a.m.- Dr. Careen Yen Lowder, M.D., Ph.D., "Fluocinolone Acetonide Intravitreal Insert in Noninfectious, Posterior Segment Uveitis: 12-Month Safety Results."
10:36 a.m. - 10:43 a.m.- Sam Mansour, M.D., "PALADIN, a Phase 4 Study with ILUVIEN: Initial Safety and Efficacy Outcomes with Intravitreal Fluocinolone Acetonide 0.2 µg/day in Diabetic Macular Edema."
11:00 a.m. - 11:07 a.m.- Daniel Kiernan, M.D., "Year 3 Visual Acuity Response in Early Nonresponders to 0.2µg/day Fluocinolone Acetonide Implants: The FAME Study."
12:45 p.m. - 1:45 p.m.- Alexander Eaton, M.D., "Real-World IOP and Cataract Surgery Outcomes following 0.19-mg Fluocinolone Acetonide Implant: USER Study." 12:45 p.m.- 1:45 p.m.- Nathan Radcliffe, M.D., "Effectiveness of Selective Laser Trabeculoplasty on Elevated IOP after 0.19-mg Fluocinolone Acetonide Implant."
12:45 p.m. - 1:45 p.m.- Lauren Mason, B.S., "Fluocinolone Acetonide Intravitreal Implant vs. Combined Vitrectomy with Implant for Chronic Diabetic Macular Edema."
12:45 p.m. - 1:45 p.m.- Dilraj Grewal, M.D., "Effect of Fluocinolone Acetonide 0.2 µg/day Implant (ILUVIEN) on the Decision to Drive in Patients with Diabetic Macular Edema."
12:45 p.m. - 1:45 p.m.- Michael Singer, M.D., "Area-Under-the-Curve Analysis of Fluocinolone Acetonide 0.2 µg/day Implant vs. Ranibizumab Plus Deferred Laser."
12:45 p.m. - 1:45 pm- Caesar Luo, M.D., "Early Anatomic vs. Long-term Vision Changes with 0.2 µg/day Fluocinolone Acetonide Implant in Diabetic Macular Edema."
Peer-to-Peer "Microdose of Reality Event,"
Lunch symposium, "Continuous DME Therapy: Clinical Evidence Through Real Word Evidence," Sunday, Nov.12, 12
ILUVIEN'S U.S. Indication
ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant approved in the U.S. to treat diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. Each ILUVIEN implant is designed to release submicrogram levels of fluocinolone acetonide, a corticosteroid, for 36 months to treat the disease consistently every day.
About Diabetic Macular Edema (DME)
DME, the primary cause of vision loss associated with diabetic retinopathy, is a disease affecting the macula, the part of the retina responsible for central vision. When the blood vessel leakage associated with diabetic retinopathy results in swelling of the macula, the condition is called DME. The onset of DME is painless and may go unreported by the patient until it manifests with the blurring of central vision or acute vision loss. The severity of this blurring may range from mild to profound loss of vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy found that over a 10-year period approximately 19% of people with diabetes included in the study were diagnosed with DME. All people with type 1 or type 2 diabetes are at risk of developing DME. As the population of people with diabetes increases, Alimera expects the annual incidence of diagnosed DME to increase, as well.
Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in Alimera’s product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.
Source: Alimera Sciences, Inc.